Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | TAAR1 | Q96RJ0 | 5/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.52 |
| ▸ | MAOA | P21397 | 1/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.52 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.52 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.52 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.52 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.50 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL97559 | 1.00 | TP53 (0.60) | TP53TSHRTAAR1MEN1KMT2A | |
| SCHEMBL3484487 | 1.00 | TP53 (0.60) | TP53TSHRTAAR1MEN1KMT2A | |
| SCHEMBL11461422 | 0.92 | TP53 (0.58) | TP53TSHRTAAR1MEN1KMT2A | |
| SCHEMBL159574 | 0.88 | TP53 (0.58) | TP53TSHRTAAR1MEN1KMT2A | |
| SCHEMBL8283176 | 0.88 | TP53 (0.58) | TP53TSHRTAAR1MEN1KMT2A | |
| SCHEMBL7931783 | 0.84 | TAAR1 (0.50) | TP53TSHRTAAR1MEN1KMT2A | |
| SCHEMBL11439830 | 0.83 | TP53 (0.53) | TP53TSHR | |
| SCHEMBL7830613 | 0.83 | CSNK1E (0.50) | TP53TSHRTAAR1MEN1KMT2A | |
| SCHEMBL26082413 | 0.83 | MAOB (0.56) | SIGMAR1MAOA | |
| SCHEMBL31412811 | 0.82 | TSHR (0.66) | TP53TSHRMEN1KMT2AEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3191112-B1 | DIPEPTIDYL KETOAMIDE COMPOUNDS AND THEIR USE FOR THE TREATMENT AND/OR PREVENTION OF FAT ACCUMULATION | LANDSTEINER GENMED S L (ES) | 2019-03-20 | — | — | EP | disclosed |
| US-20180155296-A1 | SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2018-06-07 | — | — | US | disclosed |
| US-9902702-B2 | Spirocycloheptanes as inhibitors of rock | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-02-27 | — | — | US | disclosed |
| US-9902702-B2 | Spirocycloheptanes as inhibitors of rock | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-02-27 | — | — | US | disclosed |
| US-20170058002-A1 | GAMMA-AAPEPTIDES WITH POTENT AND BROAD-SPECTRUM ANTIMICROBIAL ACTIVITY | UNIVERSITY OF SOUTH FLORIDA (US) | 2017-03-02 | — | — | US | disclosed |
| US-20170058002-A1 | GAMMA-AAPEPTIDES WITH POTENT AND BROAD-SPECTRUM ANTIMICROBIAL ACTIVITY | UNIVERSITY OF SOUTH FLORIDA (US) | 2017-03-02 | — | — | US | disclosed |
| US-9522194-B2 | Methods of using monomethylvaline compositions having phenylalanine carboxy modifications at the C-terminus | SEATTLE GENETICS, INC. (US) | 2016-12-20 | — | — | US | disclosed |
| US-20160339114-A1 | TUBULYSIN DERIVATIVES | MEDIMMUNE LLC (US) | 2016-11-24 | — | — | US | disclosed |
| US-9499587-B2 | Gamma-AApeptides with potent and broad-spectrum antimicrobial activity | UNIVERSITY OF SOUTH FLORIDA (US) | 2016-11-22 | — | — | US | disclosed |
| US-9427479-B2 | Tubulysin derivatives | MEDIMMUNE LLC (US) | 2016-08-30 | — | — | US | disclosed |
| US-7649015-B2 | Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2010-01-19 | — | — | US | disclosed |
| US-20100003732-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE 2-SUBSTITUTED PROPANAL DERIVATIVE | KANEKA CORPORATION (JP) | 2010-01-07 | — | — | US | disclosed |
| US-20090247471-A1 | INHIBITORS OF CRUZIPAIN AND OTHER CYSTEINE PROTEASES | AMURA THERAPEUTICS LTD. (GB) | 2009-10-01 | — | — | US | disclosed |
| US-20090197834-A1 | QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2009-08-06 | — | — | US | disclosed |
| US-20090192322-A1 | Tetrahydrofuro[3,2-b] pyrrol-3-one intermediates | AMURA THERAPEUTICS LIMITED (GB) | 2009-07-30 | — | — | US | disclosed |
| US-7425562-B2 | Inhibitors of cruzipain and other cysteine proteases | AMURA THERAPEUTICS LTD. (GB) | 2008-09-16 | — | — | US | disclosed |
| EP-1887085-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE 2-SUBSTITUTED PROPANAL DERIVATIVE | Kaneka Corporation (JP) | 2008-02-13 | — | — | EP | disclosed |
| WO-2008004698-A2 | PYRAZOLO [1, 5-A] PYRIMIDINE COMPOUNDS AS CB1 RECEPTOR ANTAGONIST | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-01-10 | — | — | WO | disclosed |
| US-7189864-B2 | Method of preparing intermediates useful in synthesis of retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2007-03-13 | — | — | US | disclosed |
| US-20070010489-A1 | Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds | GILEAD SCIENCES, INC. | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160339114-A1 | TUBULYSIN DERIVATIVES | TEKT1, TWF2, TEK | TP53 766/4885TSHR 3572/4885TAAR1 3796/4885 |
| US-20170058002-A1 | GAMMA-AAPEPTIDES WITH POTENT AND BROAD-SPECTRUM ANTIMICROBIAL ACTIVITY | ANPEP, DNPEP, ENPEP | TP53 3878/4885TSHR 3299/4885TAAR1 3662/4885 |
| US-20090197834-A1 | QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | P2RY12, P2RY11, P2RY10 | TP53 3598/4885TSHR 1363/4885TAAR1 1801/4885 |
| US-20090247471-A1 | INHIBITORS OF CRUZIPAIN AND OTHER CYSTEINE PROTEASES | CPN1, CTRL, CPA1 | TP53 2060/4885TSHR 2868/4885TAAR1 2959/4885 |
| US-20180155296-A1 | SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK | ROCK1, MYLK, ROCK2 | TP53 3738/4885TSHR 1625/4885TAAR1 946/4885 |
| US-20090192322-A1 | Tetrahydrofuro[3,2-b] pyrrol-3-one intermediates | CYP4F8, CYP2C8, AVPR1B | TP53 430/4885TSHR 479/4885TAAR1 1741/4885 |
| US-20070010489-A1 | Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds | PPA1, PNP, PPME1 | TP53 888/4885TSHR 4782/4885TAAR1 4780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.